Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 9, 2020

AstraZeneca pauses Covid-19 vaccine trials over suspected adverse event

AstraZeneca has put on hold all global clinical trials of its Covid-19 vaccine candidate over a suspected adverse event in a study participant.

AstraZeneca has put on hold all global clinical trials of its Covid-19 vaccine candidate over a suspected adverse event in a study participant.

The vaccine, developed by the University of Oxford, is undergoing trials in multiple countries, including the UK, South Africa, Brazil and the US.

AstraZeneca said that it voluntarily paused the trials to facilitate review of safety data by an independent committee. The move comes after a participant in the UK trial experienced an unexplained illness.

The nature of the adverse reaction was not immediately known, but the participant is expected to recover, according to STAT News citing an individual familiar with the matter.

AstraZeneca noted that the pause was a routine action and the company is working to accelerate the review of the single event to reduce any impact on the trial timeline.

In a statement, the company said: “As part of the ongoing, randomised, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.

“In large trials illnesses will happen by chance but must be independently reviewed to check this carefully.”

In July this year, AstraZeneca reported positive data from the Phase I/II COV001 clinical trial of the Covid-19 vaccine, AZD1222.

Early data showed that the vaccine candidate was tolerated and generated strong immune responses in all evaluated participants. Findings have been published in The Lancet journal.

Last month, AstraZeneca launched a Phase III trial of the vaccine candidate in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU